We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A rather unusual letter from Cel-Sci to its shareholders regarding progress on the Multikine head and neck cancer phase III trial.
https://www.firstwordpharma.com/node/1757534
Ergomed are running 2 free webinars on the patient experience & an introduction to drug development and clinical trials
- Of all the rare diseases in the world only 5% have a treatment – meaning 95% do not!
- According to the U.S. National Institutes of Health (NIH), 85% of patients are unaware of clinical trials as an option at the time of their diagnosis.
- Patients and families dealing with rare diseases will often hear about clinical trials, without understanding what the process entails.
- A lack of awareness and understanding is recognized as being one of the greatest barriers to clinical trial participation by patients.
Our experts want to dispel the mystery and confusion about clinical trials from the patients’ perspective.
Our goal is to help educate patients and their families who are dealing with rare disease, providing useful information about what is involved in clinical research.
https://www.ergomedplc.com/free-webinar-the-patient-experience-introduction-to-drug-development-and-clinical-trials/
Nice article in This is Money section of the Daily Mail featuring Ergomed:-
'At 560p a share currently, and valued overall at around £270million, Ergomed has had a good run this year, but the recent upbeat statement and growing need for its type of services suggest there is still some way to go yet. Good value.'
https://www.thisismoney.co.uk/money/investing/article-8588441/SMALL-CAP-SHARE-IDEAS-Ergomed-set-benefit-Covid-19-trials.html
HI Bermuda
Not sure if you are in here but here is tonight’s presentation.
https://www.proactiveinvestors.co.uk/upload/SponsorFile/File/2020_07/1596101439_Ergomed---Proactive-One2One-Investor-Forum-30-July-2020.pdf
Courtesy of Botski on the Scancell board, Richard Barfield will be presenting at the Proactive One2One on 30th July - you can register for the webinar here:-
https://www.proactiveinvestors.co.uk/register/event_details/260
Today's RNS...
"Aggregate of Standard Life Aberdeen plc affiliated investment management entities..." takes 7.5%.
Would I be wrong is seeing that as a signal to buy...?
Something going on - all those IIs taking positions?
Not much happening on this forum, always a good sign....keep it under the radar!
Proactive interview with Richard Barfield
https://www.youtube.com/watch?v=Fqsigkw5Y04
A cracking trading update.
- EBITDA for FY 2020 expected to be materially ahead of market expectations
- Total revenues for H1 2020 increased by 14.8%
- Sales of new business for H1 2020 increased by 22.9%
- Order book up 28% to £151.4 million
good to see how moving up today ,
some shares can be so annoying ,ncyt this morning no rns and people selling as sales update rns expected this week there with increased manufacturing to try and meet demand and £millions sales expected ,share price in red ,
that's why I now watching shares like ergo ,that in blue ,
hoping this afternoon will see more buyers at ergo
hoping
There is a free webinar at 3pm today at which one of Ergomed's experts will be talking about Covid-19, see
https://www.bigmarker.com/bioalliance-video-network/Ergomed-2020-05-263-2020-05-26-09-00-am?bmid=5ed921c22e7f
Short lived I exited yesterday at a small loss. No idea why the sp hadn’t moved just up and down 5p then looking at today’s price movements glad I had. Have searched though and I can’t see any reason but can’t sit around without a buffer. Just cut loss moved to watch list. Anyone any ideas?
Trek
I have bought in here with view to build a decent holding. Very impressive set of results, was concerned that strategic equity were selling out but may just have been profit taking in March. What I like about ERGO is it gives access to so many trials, sure it’s unlikely to ten back but following the US acquisition and strong forward sold order book it’s gonna be a steady Eddie, just what you need in this climate.
Trek
bought this and SNG today
great news there too!!
RNS out saying Siltuximab could be of benefit to serious Covid 19 sufferers. Data out of China suggests that a antibody for IL-6 could be a benefit to severe lung damage in Covid 19 patients.
CEO is still buying stock.H.C. Wainwright initiates coverage on CEL-SCI to Buy.The American Cancer Society just published a new report and says oral cancer death rates have increased over the past decade.We believe that the trial has a high probability of being successful and that the stock is deeply undervalued.
CEL-SCI Corp.'s (NYSEMKT:CVM) Phase III clinical trial of Multikine is about to end soon. We believe, through the due diligence that we have carried out, there is very little risk the primary endpoint won't be met. However, the risks of investing in a small biotech with limited cash resources and a small pipeline are well-known. The upside of a breakthrough oncology drug is what makes CEL-SCI so attractive.
History
About CEL-SCI and Multikine
CEL-SCI is a small-cap market (~$300 million) clinical-stage cancer bio-pharmaceutical company. Multikine, a ****tail combination of cytokines and chemokines, is a prospective neoadjuvant treatment and an investigational drug candidate in Phase III Event-Driven clinical development for newly diagnosed advanced primary head and neck cancer.
The goal of Multikine is to boost the body's immune system prior to Standard of Care (“SOC”). The Event-Driven Phase III study is fully enrolled with 928 patients, and the last patient was treated in September 2016.
To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events (deaths) have occurred among the two main comparator groups. We believe that this 9-year Phase III trial has just ended or will end very soon. Thus, top line results are imminent.
About The Current CRO
The current CRO, Ergomed, has a co-development agreement and has invested $12 million in this trial. The company stands to make 4x its investment if this trial is successful.
A few years into the study, Ergomed's CEO, Miroslav Reljanovic, stated:
At this point in the clinical trial we have decided to increase our investment in the development of Multikine, as we believe that it holds the potential to treat head and neck cancer in a new way. Our potential returns from this agreement will increase in line with our investment.”
It's safe to assume Ergomed's leaders have a sense of the trial's progress, and the increase in the co-development speaks volumes. With Ergomed stock more than doubling recently and significant insider buys, we believe this is a "tell". Read about it here.
https://seekingalpha.com/article/4316612-cel-sci-homestretch
Link below to proactive interview with Ergomed's CFO, Richard Barfield
https://www.youtube.com/watch?v=cfv6lSxqECQ&feature=emb_logo
ERGO's acquisition in US is a strategically significant move. Should allow ERGO to compete for larger contracts currently out of reach due to lack of US presence. Not cheap 1x rev but $10m affordable out of existing resources.
Regards Maddox
Ergomed announces the acquisition of Ashfield Pharmacovigilance Inc for $10m (cash) -
- Ashfield Pharmacovigilance Inc. reported $11.6 million revenue and $0.9 million adjusted EBITDA in the year to 30 September 2019
- is expected to be immediately accretive to earnings
- order book of contracted future revenues ("backlog") of $9.8 million
- provides a significant US pharmacovigilance presence and strengthens the US platform for the Ergomed CRO business
Good stuff.
-
-
Good opinion. Visit KillCVMShorts.com/faqs
A biotech stock that I've had in my portfolio for a while now is Cel-Sci (Nasdaq:CVM).
They're among the pioneers in the field of immunotherapy.
They're currently conducting a key, pivotal Phase-3 study (being handled by Ergomed) on their flagship product, Multikine, and the study may be nearing a conclusion.
Earlier studies have been very encouraging, so hopefully the results will continue to be positive.
I think this product has the opportunity to be a real breakthrough in cancer treatment, ...and could potentially help many people, all over the world.
just my opinion
correction
each and every time shares are allocated
SFM
A block listing is simply a facility to admit a block of unallotted shares to trading on AIM - usually to cover share options and employee benefit schemes. Basically a way of saving the administrative burden of applying to have shares admitted to trading each and every time shares they are allocated under an employee share scheme. Instead they just apply to the regulators for a block listing facility, admit the block to trading and then issue them as and when shares are granted or share options are exercised.